This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Mannarino, E. Articles by Ciuffetti, G. Search for Related Content PubMed PubMed Citation Articles by Mannarino, E. Articles by Ciuffetti, G. Pubmed/NCBI databases Substance via MeSH Social Bookmarking                         What's this?

Efficacy of Low-Molecular-Weight Heparin in the Management of Intermittent Claudication

Angiology Section, 2nd Department of Internal Medicine, University of Perugia, Perugia, Italy

Leonella Pasqualini

Angiology Section, 2nd Department of Internal Medicine, University of Perugia, Perugia, Italy

Salvatore Innocente

Angiology Section, 2nd Department of Internal Medicine, University of Perugia, Perugia, Italy

Ugo Orlandi

Angiology Section, 2nd Department of Internal Medicine, University of Perugia, Perugia, Italy

Vito Scricciolo

Angiology Section, 2nd Department of Internal Medicine, University of Perugia, Perugia, Italy

Rita Lombardini

Angiology Section, 2nd Department of Internal Medicine, University of Perugia, Perugia, Italy

Giovanni Ciuffetti

Angiology Section, 2nd Department of Internal Medicine, University of Perugia, Perugia, Italy

Treating chronic arterial occlu sive disease with heparin is contro versial because of the risks associated with long-term anticoagulant ther apy. Low molecular weight (LMW) heparin (mw about 5000 Dalton), which selectively inhibits the Xa fac tor with minimal risk of hemorrhage, seems to offer new possibilities in the prevention and treatment of both ve nous and acute arterial thromboem bolism.

Therefore, 44 patients with inter mittent claudication were recruited to a randomized, double-blind, con trolled study. Twenty-two were treated for six months with a single daily subcutaneous dose (15,000 UaXa) of LMW heparin and 22 with placebo administered in the same way over the same period of time.

After six months, LMW heparin treatment not only improved walking capacity (by lengthening the pain- free walking time by 25 %) but also significantly modified the hemor rheologic pattern (by reducing fibrin ogen concentrations and whole blood viscosity at low shear rates). LMW heparin also exerted an anti thrombotic and profibrinolytic effect by significantly increasing both the anti-Xa factor and plasminogen ac tivity without markedly modifying activated partial thromboplastin time ( + 20 %). No LMW heparin- treated patient hemorrhaged or re ported other noteworthy side effects.

These results suggest LMW hepa rin might be a useful drug in the long- term treatment of chronic arterial occlusive disease of the limbs.

Angiology, Vol. 42, No. 1, 1-7 (1991)
DOI: 10.1177/000331979104200101


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A.L. Komarov, E.P. Panchenko, A.B. Dobrovolsky, Yu.A. Karpov, A.D. Deev, E.V. Titaeva, K.K. Davletov, A.R. Eshkeeva, and L.A. Markova D-dimer and platelet aggregability are related to thrombotic events in patients with peripheral arterial occlusive disease Eur. Heart J., August 2, 2002; 23(16): 1309 - 1316. [Abstract] [PDF]

				S. Coccheri, G. Scondotto, G. Agnelli, E. Palazzini, and V. Zamboni Sulodexide in the treatment of intermittent claudication. Results of a randomized, double-blind, multicentre, placebo-controlled study Eur. Heart J., July 1, 2002; 23(13): 1057 - 1065. [Abstract] [Full Text] [PDF]

				G. Melillo, M. Scoccianti, I. Kovesdi, J. Safi Jr, T. Riccioni, and M. C Capogrossi Gene therapy for collateral vessel development Cardiovasc Res, September 1, 1997; 35(3): 480 - 489. [Abstract] [Full Text] [PDF]

				A. Calabro, F. Piarulli, D. Milan, A. Rossi, G. Coscetti, and G. Crepaldi Clinical Assessment of Low Molecular Weight Heparin Effects in Peripheral Vascular Disease Angiology, March 1, 1993; 44(3): 188 - 195. [Abstract] [PDF]